



Letter from the Editor-in-Chief: Continued Growth of the Journal

M. Maral Mouradian¹

Published online: 20 June 2022

© The American Society for Experimental NeuroTherapeutics, Inc. 2022

Neurotherapeutics, the official journal of the American Society for Experimental Neurotherapeutics, continues to grow. Since 2018, the number of submitted manuscripts has nearly doubled leading to a proportionate increase in published articles as well. In addition, the number of yearly article downloads has more than doubled. As a result of this growth, the quarterly compiled issues that include invited thematic reviews, current perspectives, and unsolicited original research articles have increased substantially in volume. Therefore, starting with this issue, we will compile two additional issues per year that would include only original research articles and accompanying commentaries, if applicable. This will allow inclusion of original research articles into a compiled issue earlier and more closely lined up with their online publication dates. The quarterly issues with reviews will continue being published in January, April, July, and October, and the two issues with research articles only will be published in March and September.

I would like to take this opportunity to announce that W. Taylor Kimberly, MD, PhD, has joined our editorial leadership team as an Associate Editor. Dr. Kimberly is Chief, Division of Neurocritical Care, Associate Professor of Neurology, Harvard Medical School, and a Faculty at the Center for Genomic Medicine at Mass General Hospital. We are delighted with this addition. He joins two highly skilled and dedicated Associate Editors: Gregory K. Bergey, MD, Professor of Neurology and Director of the Johns Hopkins Epilepsy Center, and Steven T. DeKosky, MD, Deputy Director of the McKnight Brain Institute, Aerts-Cosper Professor of

Alzheimer's Research, and Professor of Neurology and Neuroscience at the University of Florida College of Medicine.

I would also like to express my gratitude to our Editorial Board members and external peer reviewers who are instrumental in maintaining the highest standards of publications. Thanks also to our Editorial Manager Linda Powell who continues to run the editorial office with dedication since the launch of the Journal. In addition, our ongoing partnership with the production staff at Springer Nature allows for an effective collaboration to publish each issue of *Neurotherapeutics*.

My colleagues on the editorial team and I continue to strive to maintain rigorous peer review standards and publish the latest research discoveries and reviews of broad interest by key opinion leaders on current and emerging treatments of neurological disorders.

M. Maral Mouradian, MD
Editor-in-Chief

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s13311-022-01258-z>.

Required Author Form Disclosure form provided by the author is available with the online version of this article.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

✉ M. Maral Mouradian
m.mouradian@rutgers.edu

¹ RWJMS Institute for Neurological Therapeutics and Department of Neurology, Rutgers - Robert Wood Johnson Medical School, Piscataway, NJ, USA